Cardiac troponin (cTn) assays were compared in 490 unselected patients with symptoms suggestive of acute coronary syndrome with varying renal functions for risk stratification. cTnI (Dade, Newark, NJ; Beckman, Chaska, MN; and Tosoh, South San Francisco, CA) Numerous clinical trials and studies have investigated the power of cardiac troponin I (cTnI) and T (cTnT) monitoring for risk stratification of patients with acute coronary syndrome (ACS) using central laboratory and near-bedside point-of-care testing assays. 1-4 Because analytic variation has been demonstrated for all cTn assays, especially at the decisive 99th percentile reference cutoff concentration owing to lack of assay standardization and differences in total imprecision at medical decision cutoffs, understanding how assays perform in similar populations would be beneficial. [5] [6] [7] Furthermore, studies have demonstrated the influence of renal insufficiency by monitoring serum creatinine and serum cystatin C levels and creatinine clearance for predicting adverse events in patients with ACS. [8] [9] [10] In the present study, we investigated how 4 commercial cTn assays risk stratify a nonselected patient group with clinical symptoms suggestive of ACS. Unique to this study were that patients were stratified according to estimated glomerular filtration rates (eGFRs) and along sex-specific 99th percentile reference cutoffs determined in the same normal population for all cTn assays evaluated.
Numerous clinical trials and studies have investigated the power of cardiac troponin I (cTnI) and T (cTnT) monitoring for risk stratification of patients with acute coronary syndrome (ACS) using central laboratory and near-bedside point-of-care testing assays. [1] [2] [3] [4] Because analytic variation has been demonstrated for all cTn assays, especially at the decisive 99th percentile reference cutoff concentration owing to lack of assay standardization and differences in total imprecision at medical decision cutoffs, understanding how assays perform in similar populations would be beneficial. [5] [6] [7] Furthermore, studies have demonstrated the influence of renal insufficiency by monitoring serum creatinine and serum cystatin C levels and creatinine clearance for predicting adverse events in patients with ACS. [8] [9] [10] In the present study, we investigated how 4 commercial cTn assays risk stratify a nonselected patient group with clinical symptoms suggestive of ACS. Unique to this study were that patients were stratified according to estimated glomerular filtration rates (eGFRs) and along sex-specific 99th percentile reference cutoffs determined in the same normal population for all cTn assays evaluated.
Materials and Methods
We prospectively enrolled 510 consecutive, unselected patients with symptoms suggestive of ACS admitted into the Hennepin County Medical Center emergency department, a 400-bed, primary and tertiary care level 1 trauma center (Minneapolis, MN), after obtaining institutional review board (IRB) approval for the study protocol. Enrollment included patients with chest pain and other clinical features considered indicative of ACS. Patient demographics were recorded, and chart reviews or telephone follow-up interviews were carried out to determine clinical outcomes in a 6-month follow-up period.
Plasma specimens (heparin) (waste specimens along IRB guidelines) were obtained only at initial examination (baseline). Specimens were frozen at -70°C for up to 30 days until analysis. Twenty subjects were lost to follow-up, leaving 490 in the data set. Owing to short specimen volumes, the numbers of specimens evaluated by each assay were not equal, and the following numbers of specimens were analyzed by each of the following cTn assay systems: Dade Behring Dimension (Newark, NJ), n = 490; Roche Elecsys 2010 (Indianapolis, IN), n = 420; and Beckman Coulter Access (Chaska, MN), n = 421. The Tosoh AIA 200 assay (South San Francisco, CA) was added to the study after the initial design, and there were only 305 specimens available for analysis.
The median time from onset of symptoms to hospital admission (baseline plasma [heparin] specimen obtained) ranged from 3.6 to 3.9 hours. There were not significant differences between groups.
The cTnI levels were measured along manufacturer's recommended guidelines by the following assay systems: Dade, Beckman, and Tosoh. The cTnT levels were measured by the Roche system. Total imprecision rates for all assays at the 99th percentile cutoff concentrations were 12% to 22%. Plasma (heparin)-derived sex-specific 99th percentile reference limits were previously determined in 696 healthy adults, age range 18 to 84 years, 45% men and 55% women, and 58% white, 31% African American, 2% Hispanic, 5% Asian, 2% Native American, and 2% other, mixed race. 11 These reference concentrations were used for stratification in the present study: Dade, 0.06 ng/mL (0.06 µg/L) for males and females; Beckman, 0.10 ng/mL (0.10 µg/L) for males and 0.04 ng/mL (0.04 µg/L) for females; Tosoh, 0.07 ng/mL (0.07 µg/L) for males and less than 0.06 ng/mL (<0.06 µg/L) for females; and Roche, less than 0.01 ng/mL (<0.01 µg/L) for males and females. We recognize that heparin, a specimen type not recommended by Roche at the time of this study, was used for cTnT determinations for healthy control subjects and patients. eGFR values were determined based on the National Kidney Disease Education Program modification of diet in renal disease equation (mL/min/1.73 m 2 ) based on plasma creatinine level, age, sex, and whether African American. 12 Cutoffs used in stratification were less than 40, 41 to 59, and greater than or equal to 60 mL/min/1.73 m 2 . All creatinine measurements were performed on 1 of 2 Ortho Vitros 950 analyzers (Ortho, Raritan, NJ) that were highly correlated (r = 0.99). Total imprecision values were less than 6.5% for both instruments at concentrations of 0.8 and 2.1 mg/dL (71 and 186 µmol/L). Because demographic information (age and race) was not available for 6 subjects, eGFR calculations could not be performed for them.
The primary endpoint for this study was the first cardiac event (myocardial infarction) or death. Exposure was computed from the date the blood specimen was obtained until the date of the first event with censoring at the time of last contact if less than 6 months. Cumulative event rates were estimated by using the Kaplan-Meier method and compared by using the log-rank statistic. Relative risks (RRs) and 95% confidence intervals (CIs) were estimated by using Cox proportional hazards models. Statistical significance was accepted at the .05 level, and all statistical tests were 2-sided. Statistical analyses were performed with SPSS for Windows, version 11.5 (SPSS, Chicago, IL).
Results
The average patient age was 58.3 years (range, 17-97 years), 57% were male, and 35% were African American. A history of hypertension was noted in 62% and diabetes in 26%. The mean eGFR was 77 mL/min/1.73 m 2 , with 68% having an eGFR of at least 60, 17% between 41 and 59, and 15% at 40 or less. Patient characteristics for each assay group were similar ❚Table 1❚. A total of 36 deaths and 9 cardiac events occurred in 38 patients within 6 months of presentation, resulting in a 6-month event rate of 9.8%. Risk stratification by normal vs increased cTn level for the combined endpoint was significant at 30 days using any of the 4 assays (all P ≤ .05) ❚Figure 1❚. At 6 months, risk stratification was again significant for the Dade cTnI, Beckman cTnI, Tosoh cTnI, and Roche cTnT assays with event rates in the increased cTn group ranging from 22.4% to 24.2% vs 6.7% to 8.9% in the normal group (all P ≤ .001) ❚Table 2❚ (Figure 1 ). The Roche cTnT assay identified approximately 25% of patients as having an increased cTn level, 1.5 to 2 times greater that identified by the cTnI assays (P < .05). Increased risk of cardiac event or mortality associated with an increased cTnI or cTnT level is about 3-fold (RR estimates, 3.1-3.7). Considering only women, an increased cTn level as evaluated by each of the 4 assays was associated ❚Figure 1❚ Kaplan-Meier combined cardiac event and mortality status curves of 3 cardiac troponin I (cTnI) assays and 1 cardiac troponin T (cTnT) assay stratified according to sex-derived 99th percentile reference limit concentrations. The following are numbers of patients at risk (because of symptoms of acute coronary syndrome) with normal and increased cTn levels, respectively. A, Dade cTnI, baseline, 418 and 72; at 6 months, 233 and 39 (P < .001). B, Roche cTnT, baseline, 314 and 106; at 6 months, 173 and 55 (P < .001). C, Tosoh cTnI, baseline, 248 and 57; at 6 months, 135 and 30 (P = .01). D, Beckman cTnI, baseline, 364 and 57; at 6 months, 199 and 29 (P < .001). For proprietary information, see Table 1 .
with an increased risk of cardiac event or mortality (all P ≤ .01) ❚Table 3❚; 6-month event rates in the increased cTn group ranged from 21.0% to 26.1% compared with 3.6% to 5.1% in the normal group. The proportion of women with an increased cTn level ranged from 14.1% to 20.1% and was not significantly different by assay (P < .05).
Renal impairment was associated with increased risk of cardiac event and mortality (P < .001); the RR values 3.3 (95% CI, 1.4-8.0) for an eGFR of 41 to 59 mL/min/1.73 m 2 and 7.9 (95% CI, 3.7-16.7) for an eGFR less than 40 mL/min/1.73 m 2 compared with patients with an eGFR of 60 mL/min/1.73 m 2 or more. After stratifying by eGFR level, an increased cTn level remained important in risk stratification, particularly for patients with eGFR levels less than 60 mL/min/1.73 m 2 ❚Table 4❚. The 6-month event rates for patients with an eGFR of less than 60 mL/min/1.73 m 2 for normal vs increased cTn levels were 14.0% vs 40.0% (P < .001), 12.5% vs 30.4% (P = .03), 15.6% vs 42.6% (P = .001), and 9.6% vs 34.4% (P = .006) for the Dade cTnI, Roche cTnT, Beckman cTnI, and Tosoh cTnI assays, respectively. Event rates for patients with an eGFR of 60 mL/min/1.73 m 2 or more, however, were not different between patients with normal vs increased cTn levels as measured by any of the assays.
Discussion
In a heterogeneous group of nonpreselected patients with symptoms suggestive of ACS, 4 commercial cTn assays independently predicted adverse outcomes for adverse events when the cTn level was more than the sex-specific 99th percentile reference limits. Unique observations were also observed for the added risk stratification potential when cTnI and cTnT were simultaneously measured and for the added power of monitoring eGFR along with cTn levels for risk stratifying patients. Our findings are unique because they are based on 99th percentile reference cutoffs derived by sex from the same normal population for all assays, adding to and confirming the evidence-based literature substantiated on individual cTn assays that have been evaluated in clinical trials. 1, 2, 13, 14 We used the European Society of Cardiology/American College of Cardiology recommended 99th percentile cutoff for detection of myocardial injury, 6, 15 with the knowledge that in risk assessment, low cTn concentrations are significant predictors of adverse events and that at low concentrations, more events are detected compared with higher receiver operating characteristic curve cutoffs optimized for clinical sensitivity and specificity along previous World Health Organization criteria for detection of myocardial infarction. 16, 17 Our study also demonstrates that in a subset of women, increased cTn concentrations were able to risk stratify for adverse events. Furthermore, we observed within the overall population studied that cTnT demonstrated a 2-fold higher percentage of people at risk and that when considered with cTnI, there was a significantly greater risk of adverse events when levels of both biomarkers were increased compared with an increase in only one value.
Adverse events were particularly influenced by renal function, as assessed by eGFR. Although significantly greater risk for adverse events was found by all assays when a decreased eGFR was paired with an increased cTn level, we observed that only in the group with an eGFR of 40 mL/min/1.73 m 2 or more were adverse events stratified along increases vs decreases in the cTn level. Our findings were in contrast with those of Aviles et al, 9 who found that cTnT levels predicted the 30-day prognosis in patients with ACS regardless of their creatinine clearance. However, our study is different because our patient group was not highly selected for ACS but represented a more heterogeneous group admitted through an emergency department. At present, we are not able to offer an explanation of this intriguing finding. However, our findings add to those of previous studies that have shown impaired renal status independently risk stratifies patients with ACS. [8] [9] [10] We recognize several limitations. First, the study's sample was not large. Although sample sizes varied between assays owing to specimen volumes issues, demographics did not differ between groups. However, our data support the findings of published large and smaller studies. Second, clinical data regarding medications and electrocardiographic findings were not independently assessed in a multivariate analysis. Third, only the baseline admission specimen was studied because an additional serial sampling at more than 6 hours was not available. Fourth, unstable angina was not included as an outcome measure.
It is important to publish evidence-based findings documenting outcomes for each cTn assay sold in the marketplace in as standardized a protocol as possible. The findings of the present study that emphasize the importance of sex-derived cutoffs and the role of eGFR in stratification should assist laboratories and clinicians in their use and interpretation of these 4 cTn assays in all clinical settings, especially with admissions through the emergency department, for determining appropriate triage, diagnostics, management, therapy, and risk-stratification protocols.
